For U.S. Healthcare Professionals Only
PRESCRIBING INFORMATION PRESCRIBING INFORMATION XYZ'S OF XYZAL ONCE-DAILY DOSING SAFETY INFORMATION REIMBURSEMENT ORAL SOLUTION
XYZ'S OF XYZAL
XYZ'S OF XYZAL
Dr. Porter
Reimbursement

You can help your patients save up to $100 on prescriptions of XYZAL®. Ask your UCB or sanofi-aventis representative about the XYZAL eXperience card program today. Your representative can provide you with a XYZAL Challenge Kit, which includes XYZAL eXperience cards to distribute to patients. You can also click here to request a set of 10 cards.

The eXperience card provided will allow patients to save up to $100 on their XYZAL prescriptions—up to $20 off 5 prescriptions. Patients simply call 1–866–484–6834 to activate the card upon receipt. They then present the card to the pharmacist when filling a prescription, and up to $20 will be deducted from their out–of–pocket expense.

Read about the full eligibility requirements here.

If a pharmacist is unable to provide this instant rebate to eligible patients, the patients can still take advantage of this offer: On the original pharmacy receipt, they must circle the product name, date, and amount paid. They then can mail the receipt, with their XYZAL eXperience Card and their full name and address, to: XYZAL $20 Rebate Offer, UCB, Inc. and sanofi–aventis U.S. LLC, PO Box 12029, Trenton, NJ 08650. We will reply with a check in four to six weeks.


Print this page
Make text larger
XYZAL has 6 years of
post-marketing experi-
ence and more than
1.3 billion patient-days
worldwide.1
1Data on file, UCB, Inc.
 

Indications and Important Safety Information

XYZAL is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.

The use of XYZAL is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal impairment at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis; and pediatric patients aged 6 to 11 years with impaired renal function.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, after ingestion of XYZAL. Concurrent use of XYZAL with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.

In clinical trials, the most common adverse reactions in ≥2% of adult and adolescent patients (12 years of age and older) taking XYZAL 2.5 mg, XYZAL 5 mg, or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.

In clinical trials, the most common adverse reactions in ≥2% of pediatric patients (6-12 years of age) taking XYZAL 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs <1% placebo), somnolence (3% vs <1% placebo), and epistaxis (2% vs <1% placebo).

XYZAL® is a trademark of UCB Group of companies.
© 2008 UCB, Inc. and sanofi-aventis U.S. LLC. All rights reserved. X1104-0808

Last Updated: July 2008
sanofi aventis logo
Home | Terms of Use | Privacy Policy | Medical Information 1-866-822-0068 | Contact Us 1–888–NOW–XYZAL (1–888–669–9992)

Close